Search Results for "DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer"

DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

Considerations for molecular testing for HER2+ gastric cancer

Trastuzumab Deruxtecan for Patients w/ HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?

The significance of HER2 expression for the activity of trastuzumab deruxtecan

FDA approves fam-trastuzumab deruxtecan-nxki for HER2 positive gastric adenocarcinomas

Trastuzumab Deruxtecan in HER2+ Breast Cancer

Recent advances in gastrointestinal research: DESTINY-Gastric01 and Spotlight

HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Analyzing the DESTINY-Gastric01 Trial for Gastric or GEJ Adenocarcinoma

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu in GI cancers

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer